Short Interest in Conexeu Sciences Inc. (NASDAQ:CNXU) Increases By 357.1%

Conexeu Sciences Inc. (NASDAQ:CNXU) saw a significant growth in short interest in the month of July. As of July 15th, there was short interest totaling 170,673 shares, a growth of 357.1% from the June 30th total of 37,335 shares. Approximately 0.6% of the company’s stock are short sold. Based on an average daily trading volume, of 156,558 shares, the days-to-cover ratio is presently 1.1 days.

Conexeu Sciences Trading Down 10.4%

NASDAQ:CNXU opened at $7.68 on Tuesday. The firm has a market cap of $205.50 million and a P/E ratio of -69.82. Conexeu Sciences has a twelve month low of $7.30 and a twelve month high of $18.79. The business’s 50 day moving average price is $11.62.

Conexeu Sciences (NASDAQ:CNXU) last posted its quarterly earnings data on Monday, June 15th. The company reported ($0.11) earnings per share (EPS) for the quarter.

Wall Street Analyst Weigh In

A number of research firms have issued reports on CNXU. Zacks Research upgraded Conexeu Sciences to a “hold” rating in a report on Monday, June 29th. HC Wainwright assumed coverage on Conexeu Sciences in a research note on Monday, June 22nd. They issued a “buy” rating and a $20.00 price target on the stock. Finally, Wall Street Zen upgraded Conexeu Sciences to a “hold” rating in a report on Saturday, May 30th. One research analyst has rated the stock with a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $20.00.

Insider Buying and Selling at Conexeu Sciences

In related news, Director Lynn Sebastian Purcell acquired 202,500 shares of the stock in a transaction dated Thursday, June 18th. The stock was bought at an average price of $0.80 per share, with a total value of $162,000.00. Following the completion of the transaction, the director directly owned 2,734,240 shares of the company’s stock, valued at approximately $2,187,392. The trade was a 8.00% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Conexeu Sciences Company Profile

Conexeu is a company focused on building a new class of collagen-based regenerative tissue products. The Company was incorporated on November 2, 2022 under the Business Corporations Act (British Columbia) and was continued out of British Columbia and domesticated into the State of Nevada under the laws of the State of Nevada on April 10, 2025. — Conexeu is an early-stage medical device company formed to acquire and commercialize intellectual property (“IP”) developed over more than a decade at the University of British Columbia (the “University”) and the BC Professional Firefighters Burn and Wound Healing Laboratory.